Compare · CDNA vs HUM
CDNA vs HUM
Side-by-side comparison of CareDx Inc. (CDNA) and Humana Inc. (HUM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDNA and HUM operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $46.80B, about 17.8x CDNA ($2.63B).
- Over the past year, CDNA is up 297.0% and HUM is up 30.1% - CDNA leads by 266.9 points.
- CDNA has been more active in the news (11 items in the past 4 weeks vs 6 for HUM).
- HUM has more recent analyst coverage (25 ratings vs 19 for CDNA).
- Company
- CareDx Inc.
- Humana Inc.
- Price
- -
- -
- Market cap
- $2.63B
- $46.80B
- 1M return
- +39.77%
- +2.03%
- 1Y return
- +297.03%
- +30.12%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 11
- 6
- Recent ratings
- 19
- 25
CareDx Inc.
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors. CareDx, Inc. has a license agreement with Illumina, Inc. for the distribution, development and commercialization rights to NGS products and technologies; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Latest CDNA
- Amendment: SEC Form SCHEDULE 13G/A filed by CareDx Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by CareDx Inc.
- SEC Form SCHEDULE 13G filed by CareDx Inc.
- Director Bickerstaff George sold $925,700 worth of shares (20,000 units at $46.28), decreasing direct ownership by 13% to 134,061 units (SEC Form 4)
- Director Cournoyer Christine sold $750,973 worth of shares (16,000 units at $46.94), decreasing direct ownership by 27% to 42,943 units (SEC Form 4)
- Secretary and General Counsel Novack Jeffrey Adam sold $124,349 worth of shares (2,688 units at $46.26) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,075 units (SEC Form 4)
- Director Goldberg Michael sold $2,103,497 worth of shares (44,700 units at $47.06), decreasing direct ownership by 42% to 61,738 units (SEC Form 4)
- Secretary and General Counsel Novack Jeffrey Adam covered exercise/tax liability with 2,872 shares, decreasing direct ownership by 3% to 108,763 units (SEC Form 4) (for withholding tax)
- SEC Form 144 filed by CareDx Inc.
- SEC Form 144 filed by CareDx Inc.
Latest HUM
- Humana Names Dr. Shantanu Nundy as Chief Medical Officer
- James P. Holland to Join Humana as Medicaid President
- Humana upgraded by Morgan Stanley with a new price target
- Humana Subsidiary iCare Selected for Family Care and Family Care Partnership Contracts Across Southeast Wisconsin
- Director Smith Paul John was granted 544 units of Humana Common (SEC Form 4)
- Director Crawford Frederick John was granted 544 units of Humana Common (SEC Form 4)
- Humana upgraded by Evercore ISI with a new price target
- Humana upgraded by Leerink Partners with a new price target
- Humana downgraded by Raymond James
- New insider Crawford Frederick John claimed ownership of 21 units of Humana Common (SEC Form 3)